Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus LEXETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus LEXETTE.
DERMA-SMOOTHE/FS vs LEXETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
LEXETTE (halobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. The primary mechanism involves binding to glucocorticoid receptors, which modulates gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Apply to affected areas once daily for up to 2 weeks. Use no more than 60 g per week.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Terminal elimination half-life is 12-15 hours, supporting twice-daily dosing in clinical practice.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Primarily renal excretion of unchanged drug (approximately 70%), with 30% metabolized hepatically via CYP3A4 and excreted as inactive metabolites in urine and feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid